
    
      Patients will undergo two weeks of prospective observation, they will then receive IV
      infusions of ketamine, scopolamine or both per randomization as augmentation of their ongoing
      antidepressant regime. The schedule of administration will be twice a week of three weeks.
      After this phase the subject will be followed with assessments every two weeks for three
      months.
    
  